Adherence to antiviral treatment among people living with chronic hepatitis B: A global survey

Table 3 Sociodemographic characteristics of survey respondents based on treatment adherence, n (%)¹

Characteristics	Overall	High adherence	Low adherence	P value (χ2)
n	614 (100.0)	496 (80.8)	118 (19.2)
Age (years)				0.099
18-30	180 (29.3)	147 (81.7)	33 (18.3)
31-45	290 (47.2)	225 (77.6)	65 (22.4)
46 and above	144 (23.5)	124 (86.1)	20 (13.9)
Gender				0.58
Male	480 (78.2)	390 (81.3)	90 (18.8)
Female	134 (21.8)	106 (79.1)	28 (20.9)
Ethnicity				0.008
White/Other	109 (17.8)	94 (86.2)	15 (13.8)
African/African American	322 (52.4)	245 (76.1)	77 (23.9)
AANHPI2	183 (29.8)	157 (85.8)	26 (14.2)
WHO region				0.16
Africa	295 (48.5)	231 (78.3)	64 (21.7)
Western Pacific	42 (6.9)	32 (78.2)	10 (23.8)
Southeast Asia	76 (12.5)	67 (88.2)	9 (11.8)
Middle East	34 (5.6)	26 (76.5)	8 (23.5)
Europe	32 (5.3)	29 (90.6)	3 (9.4)
North America/Americas3	129 (21.2)	109 (84.5)	20 (15.5)
Education				0.17
High school or less	64 (10.4)	55 (85.9)	9 (14.1)
Technical/vocational/some college	64 (10.4)	55 (85.9)	9 (14.1)
College graduate	250 (40.7)	192 (76.8)	58 (23.2)
Postgraduate	236 (38.4)	194 (82.2)	42 (17.8)
Lives in a large city				0.42
No	234 (47.4)	183 (78.2)	51 (21.8)
Yes	260 (52.6)	211 (81.2)	49 (18.9)

¹Treatment adherence is defined by participant reports of how often they miss their hepatitis B medication. Missing medication every other day or once a week were categorized as low treatment adherence and missing medications once a month, a few times a year, and never were categorized as high treatment adherence.

²AANHPI (Asian, Asian American, Native Hawaiian, and Pacific Islanders).

³North America and South America combined due to small South American sample size (1% of sample).

WHO: World Health Organization.